or Try an Advanced Search...

    Technical Analysis for CPRX - Catalyst Pharmaceutical Partners, Inc.

    Grade Last Price % Change Price Change
    C 15.20 1.00% 0.15
    CPRX closed up 1.0 percent on Wednesday, May 1, 2024, on 77 percent of normal volume.
    Earnings due: May 8
    *** please verify all earnings dates ***
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Up
    Historical CPRX trend table...
    Date Alert Name Type % Chg
    20 DMA Resistance Bearish 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    Bollinger Band Squeeze Range Contraction 1.00%
    NR7 Range Contraction 1.00%
    NR7-2 Range Contraction 1.00%
    Narrow Range Bar Range Contraction 1.00%
    Gapped Down Weakness 1.00%
    Bollinger Band Squeeze Range Contraction -0.20%
    NR7 Range Contraction -0.20%
    NR7-2 Range Contraction -0.20%
    Older End-of-Day Signals for CPRX ...

       Recent Intraday Alerts

    Alert Time
    Up 3% about 5 hours ago
    60 Minute Opening Range Breakout about 8 hours ago
    Up 2% about 9 hours ago
    Rose Above 20 DMA about 10 hours ago
    20 DMA Resistance about 10 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    CPRX Chart by TradingView
    Basic chart:

    Profile

    Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. It focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. The company's principal product includes Firdapse that is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. It also develops CPP-115, a GABA aminotransferase inhibitor for the treatment of epilepsy and other selected central nervous disease indications; and CPP-109 for the treatment of Tourette Syndrome. Catalyst Pharmaceutical Partners, Inc. has strategic collaboration agreement with BioMarin. The company was founded in 2002 and is based in Coral Gables, Florida.
    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Pharmaceutical Health Sciences Medication Virotherapy Disorders Epilepsy Pharmaceutical Sciences Prescription Drugs Stage Specialty Pharmaceutical Myasthenia Pharmaceutical Partners Treatment Of Epilepsy Lambert Eaton Myasthenic Lambert Eaton Myasthenic Syndrome Tourette Syndrome Treatment Of Tourette Syndrome Urological Diseases

    Is CPRX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 1 Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
    Apr 24 Dirt-Cheap Delights: 3 Discounted Stocks That Could Triple by 2026
    Apr 22 Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
    Apr 18 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is largely controlled by institutional shareholders who own 65% of the company
    Apr 13 Jim Cramer’s 10 Favorite Healthcare Stock Picks in 2024
    Apr 6 Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)
    Mar 29 Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?
    Mar 28 Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
    Mar 27 Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
    Mar 27 3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
    See more CPRX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 17.765
    52 Week Low 11.09
    Average Volume 1,366,902
    200-Day Moving Average 14.24
    50-Day Moving Average 15.57
    20-Day Moving Average 15.30
    10-Day Moving Average 15.05
    Average True Range 0.55
    RSI (14) 48.45
    ADX 14.91
    +DI 19.00
    -DI 18.71
    Chandelier Exit (Long, 3 ATRs) 14.59
    Chandelier Exit (Short, 3 ATRs) 16.25
    Upper Bollinger Bands 16.01
    Lower Bollinger Band 14.58
    Percent B (%b) 0.43
    BandWidth 9.34
    MACD Line -0.16
    MACD Signal Line -0.14
    MACD Histogram -0.0207
    Fundamentals Value
    Market Cap 1.81 Billion
    Num Shares 119 Million
    EPS 0.55
    Price-to-Earnings (P/E) Ratio 27.64
    Price-to-Sales 4.66
    Price-to-Book 4.66
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 16.03
    Resistance 3 (R3) 16.04 15.78 15.89
    Resistance 2 (R2) 15.78 15.57 15.77 15.84
    Resistance 1 (R1) 15.49 15.44 15.64 15.48 15.80
    Pivot Point 15.23 15.23 15.30 15.22 15.23
    Support 1 (S1) 14.94 15.02 15.09 14.93 14.60
    Support 2 (S2) 14.68 14.89 14.67 14.56
    Support 3 (S3) 14.39 14.68 14.51
    Support 4 (S4) 14.38